Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.47 AUD | -1.59% | 0.00% | +29.66% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company sustains low margins.
- The company is in debt and has limited leeway for investment
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+29.66% | 382M | B+ | ||
-17.89% | 8.36B | B+ | ||
+40.49% | 3.6B | C+ | ||
-32.64% | 2.73B | B- | ||
-7.88% | 2.47B | - | ||
-7.35% | 2.32B | B- | ||
-14.40% | 1.77B | C- | ||
-18.74% | 1.55B | A- | ||
-40.19% | 1.22B | C+ | ||
+5.57% | 1.09B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IDX Stock
- Ratings Integral Diagnostics Limited